Web7 nov. 2024 · Following positive Phase II data, Roche is planning to take an Ionis-developed antisense drug candidate into a late-stage clinical trial in the first part of 2024. … Web18 jan. 2024 · Roche has outlined a new clinical path forward for a closely watched Huntington's disease drug ten months after disappointing Phase 3 study results …
Roche pays $55M for late-stage drug for rare kidney disease with …
Web12 mei 2024 · Regeneron’s Evkeeza (evinacumab-dgnb) is the first mAb approved for familial hypercholesterolemia that targets the angiopoietin-like 3 protein. A double dose of bad news came in Huntington’s... Web22 mrt. 2024 · In December 2024, Roche licensed the investigational molecule from Ionis Pharmaceuticals. Tominersen is being investigated in HD in the following clinical studies: inconsistency\u0027s cn
Roche Licenses Promising Huntington
Web11 okt. 2024 · Ionis Pharmaceuticals is on a roll.Days after securing regulatory approval from the U.S. Food and Drug Administration (FDA) for Tegsedi, the company inked a … Web18 jan. 2024 · Dive Brief: Roche has outlined a new clinical path forward for a closely watched Huntington's disease drug ten months after disappointing Phase 3 study results appeared to spell the end for the experimental medicine, known as tominersen.; According to a statement from development partner Ionis Pharmaceuticals, Roche, after reviewing … Web16 mei 2024 · We, Roche, Biogen and Ionis, are amongst several companies working towards finding potential treatments for Angelman Syndrome (AS). While Roche and the Biogen/Ionis team have two independent research programs, we all share the common goal of bringing potential new therapies for AS into clinical trials in the future. inconsistency\u0027s cr